US-CONGRESS HR7895: PBM Kickback Prohibition Act
HR7895 aims to prohibit kickbacks in pharmacy benefit manager (PBM) contracts, affecting how independent and chain pharmacies negotiate reimbursement. The bill is on the Union Calendar, indicating progress toward a floor vote.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies should confirm how it applies to their specific situation before acting. There is a time constraint attached: No immediate deadline; monitor legislative progress for floor vote and potential enactment.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The bill would ban PBMs from receiving kickbacks or fees based on drug price spreads, potentially altering reimbursement models and contract terms.
Who it affects
Independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies
What you must do
Review current PBM contracts for any kickback or spread-based compensation structures and prepare for potential renegotiation.
Deadline
No immediate deadline; monitor legislative progress for floor vote and potential enactment.
Source: https://www.congress.gov/bill/119th-congress/house-bill/7895
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
- Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
- Amanda Ward, N.D.; Decision and Order